Literature DB >> 23269607

Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia.

Farhad Jadidi-Niaragh1, Ghasem Ghalamfarsa, Ali Memarian, Hossein Asgarian-Omran, Seyed Mohsen Razavi, Abdolfattah Sarrafnejad, Fazel Shokri.   

Abstract

Little is known about the immunobiology of interleukin-17 (IL-17)-producing T cells and regulatory T cells (Treg) in chronic lymphocytic leukemia (CLL). In this study, the frequencies of Th17, Tc17, and CD39(+) Treg cells were enumerated in peripheral T cells isolated from 40 CLL patients and 15 normal subjects by flow cytometry. Our results showed a lower frequency of Th17 and Tc17 cells in progressive (0.99 ± 0.12 % of total CD3(+)CD4(+) cells; 0.44 ± 0.09 % of total CD8(+) cells) compared to indolent patients (1.57 ± 0.24 %, p = 0.042; 0.82 ± 0.2 %, p = 0.09) and normal subjects (1.78 ± 0.2 %, p = 0.003; 0.71 ± 0.09 %, p = 0.04). Decrease in IL-17-producing T cells was associated with CD39(+) Treg cells expansion. Variation of IL-17-producing cells and Treg cells in indolent and progressive patients was neither associated to the expression levels of Th1- and Th2-specific transcription factors T-bet and GATA-3 nor to the frequencies of IFN-γ and IL-4-producing CD4(+) T cells in a selected number of samples. Additionally, suppressive potential of CD4(+) Treg was similar in CLL patients and normal subjects. Our data indicate that progression of CLL is associated with downregulation of IL-17-producing T cells and expansion of Treg cells, implying contribution of these subsets of T cells in the progression of CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269607     DOI: 10.1007/s13277-012-0628-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  66 in total

Review 1.  Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.

Authors:  Mohamed A Kharfan-Dabaja; Julio C Chavez; Khadija A Khorfan; Javier Pinilla-Ibarz
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

2.  Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Krzysztof Giannopoulos; Michael Schmitt; Malgorzata Kowal; Paulina Wlasiuk; Agnieszka Bojarska-Junak; Jinfei Chen; Jacek Rolinski; Anna Dmoszynska
Journal:  Oncol Rep       Date:  2008-09       Impact factor: 3.906

Review 3.  Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective.

Authors:  Casey T Weaver; Robin D Hatton
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

4.  Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity.

Authors:  Manjunatha Ankathatti Munegowda; Yulin Deng; Sean J Mulligan; Jim Xiang
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

5.  Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan.

Authors:  K Tamura; H Sawada; Y Izumi; T Fukuda; A Utsunomiya; S Ikeda; N Uike; J Tsukada; F Kawano; T Shibuya; H Gondo; S Okamura; J Suzumiya
Journal:  Eur J Haematol       Date:  2001-09       Impact factor: 2.997

6.  Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients.

Authors:  Dong-Ming Kuang; Chen Peng; Qiyi Zhao; Yan Wu; Ling-Yan Zhu; Jianen Wang; Xiao-Yu Yin; Lian Li; Limin Zheng
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

7.  Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma.

Authors:  Michael G Alexandrakis; Constantina A Pappa; Spiros Miyakis; Aikaterini Sfiridaki; Maria Kafousi; Athanassios Alegakis; Efstathios N Stathopoulos
Journal:  Eur J Intern Med       Date:  2006-10       Impact factor: 4.487

8.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

9.  T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation.

Authors:  Ming O Li; Yisong Y Wan; Richard A Flavell
Journal:  Immunity       Date:  2007-05-03       Impact factor: 31.745

10.  CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism.

Authors:  Zhi-Jian Ye; Qiong Zhou; Jian-Chu Zhang; Xiao Li; Cong Wu; Shou-Ming Qin; Jian-Bao Xin; Huan-Zhong Shi
Journal:  Respir Res       Date:  2011-06-10
View more
  25 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 2.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

3.  Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.

Authors:  Byeongho Jung; Gerardo Ferrer; Pui Yan Chiu; Rukhsana Aslam; Anita Ng; Florencia Palacios; Michael Wysota; Martina Cardillo; Jonathan E Kolitz; Steven L Allen; Jacqueline C Barrientos; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal:  JCI Insight       Date:  2022-06-22

Review 4.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

Review 5.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

6.  Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.

Authors:  Gayathri Natarajan; Cesar Terrazas; Steve Oghumu; Sanjay Varikuti; Jason A Dubovsky; John C Byrd; Abhay R Satoskar
Journal:  Oncoimmunology       Date:  2015-06-09       Impact factor: 8.110

Review 7.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

8.  Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.

Authors:  Alak Manna; Timothy Kellett; Sonikpreet Aulakh; Laura J Lewis-Tuffin; Navnita Dutta; Keith Knutson; Eduardo Chini; Javier Pinilla-Ibarz; Nicole Lamanna; Rami Manochakian; Fabio Malavasi; Taimur Sher; Asher A Chanan-Khan; Sikander Ailawadhi; Aneel Paulus
Journal:  Blood Adv       Date:  2020-05-26

9.  The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.

Authors:  Ping Chen; Min Wang; Daqi Li; Yan Jia; Na He; Wei Li; Daoxin Ma; Chunyan Ji
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

Review 10.  Th17 and Treg cells in bone related diseases.

Authors:  Min Wang; Tian Tian; Shuang Yu; Na He; Daoxin Ma
Journal:  Clin Dev Immunol       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.